HeartBeam Pursues Multiple Regulatory Paths After FDA Rejects 12-Lead ECG Synthesis Software Application
Key Insights
HeartBeam received a Not Substantially Equivalent (NSE) decision from the FDA on its 510(k) submission for 12-lead ECG synthesis software (search), prompting the company to explore multiple regulatory pathways.
The company's VALID-ECG clinical study met its agreed-upon endpoints, and HeartBeam believes labeling modifications can address the FDA's outstanding concerns.
HeartBeam plans to pursue parallel approaches including an appeal process with a 60-day timeline or resubmission of a new 510(k) application.
HeartBeam, Inc. (NASDAQ: BEAT) announced its regulatory strategy following the Food and Drug Administration's Not Substantially Equivalent (NSE) decision on the company's 510(k) submission for its 12-lead Electrocardiogram (ECG) Synthesis Software. The medical technology company is now pursuing multiple parallel regulatory paths to secure approval for its innovative cardiac monitoring technology.
FDA Engagement and Response Strategy
Following receipt of the NSE letter, HeartBeam has been actively engaging with FDA review staff to understand the agency's concerns and determine the optimal path forward. The FDA has signaled a willingness to work with the company towards a constructive resolution, according to the company's announcement.
"HeartBeam appreciates the extensive interactions with the FDA on the HeartBeam 12-lead Synthesis Software," said Robert Eno, Chief Executive Officer of HeartBeam. "We have engaged in good faith with the agency over a period of two years and have had extremely positive interactions. Together with the agency, we resolved the vast majority of open questions."
Clinical Evidence and Regulatory Options
The company stands behind its VALID-ECG clinical study, which was submitted in support of the application and met its clinical endpoints. HeartBeam believes it has a viable argument to address the FDA's outstanding concerns and that these issues can be resolved through modifications to the proposed device labeling.
The range of regulatory options being pursued includes an appeal process or resubmission of a 510(k) application. Based on recent discussions with the FDA, the company believes there is a viable path forward under an appeal process, which has an official timeline of approximately 60 days from submission to resolution.
Technology Platform and Recent Approvals
HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar dimensions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located to deliver actionable heart intelligence.
The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The currently cleared HeartBeam System (search) is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead electrocardiogram acquired from 5 electrodes. The device is intended for use by adult patients in either clinical settings or at home and can be used with ECG Viewer software for manual interpretation of non-life-threatening arrhythmias by physicians or healthcare professionals.
Commercial and Development Outlook
While the regulatory process moves forward, HeartBeam plans to continue providing shareholders with updates on commercial launch and funding plans. The company holds over 20 issued patents related to its technology enablement and aims to transform the detection and monitoring of critical cardiac conditions by enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
Eno emphasized the company's commitment to resolving the regulatory challenges: "After assessing our options, we believe that the best way to resolve the open questions and to get this technology into the hands of patients is to engage in the multiple paths available for constructive resolution. Since the remaining concerns from the FDA are well defined and can be readily addressed by our team, we believe these paths can lead to a favorable resolution."